Welcome to our dedicated page for Aethlon Medical news (Ticker: AEMD), a resource for investors and traders seeking the latest updates and insights on Aethlon Medical stock.
Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California, with news flow centered on development of its investigational Hemopurifier device. Company announcements highlight progress in oncology and infectious disease programs, capital markets activity, and regulatory interactions that shape the outlook for AEMD stock.
Recent news releases describe Aethlon’s ongoing safety, feasibility, and dose-finding oncology trial in Australia, where the Hemopurifier is being evaluated in patients with solid tumors who have not responded to anti-PD-1 therapies. Updates have covered early observations on extracellular vesicles, microRNAs, and lymphocyte counts in initial cohorts, along with protocol amendments and site activity. The company also reports collaborations in Long COVID research, including preclinical data showing that its GNA affinity resin binds extracellular vesicles in Long COVID plasma and depletes EV-associated microRNAs linked to inflammatory pathways.
Investors following AEMD news will also see regular disclosures on financing transactions, such as public offerings and private placements of common stock, pre-funded warrants, and common stock purchase warrants. These items detail gross proceeds, warrant terms, and intended uses of capital for clinical trials, research and development, and working capital. Additional coverage includes patent issuances related to Long COVID and COVID-19-associated coagulopathy, Nasdaq listing compliance updates, and scheduling of quarterly financial results and conference calls.
This news page aggregates Aethlon Medical’s press releases and related coverage so readers can review clinical updates, scientific publications, financing events, and regulatory milestones in one place. For those tracking AEMD, it offers a structured view of how the company communicates progress on the Hemopurifier and its broader development strategy over time.
Aethlon Medical (NASDAQ: AEMD) announced the independent DSMB completed a safety review of cohort 2 in its AEMD-2022-06 trial on March 24, 2026 and recommended advancing to cohort 3. No device-related SAEs or DLTs were reported and cohort 3 enrollment is open to receive three Hemopurifier treatments over one week.
The study (9–18 patients) evaluates safety, feasibility and dose-finding in patients with solid tumors receiving pembrolizumab or nivolumab, with primary endpoints focused on adverse events and safety labs.
Aethlon Medical (Nasdaq: AEMD) reported that an independent DSMB completed a safety review of cohort 2 in its AEMD-2022-06 oncology trial and recommended advancing to the third and final cohort. The DSMB found no safety concerns, with no device-related SAEs or DLTs reported to date.
Enrollment for Cohort 3 is open; participants will receive three Hemopurifier treatments over one week at three active clinical sites in Australia. Results will inform a future PMA study.
Aethlon Medical (Nasdaq: AEMD) has engaged Maxim Group LLC as exclusive financial advisor to evaluate strategic opportunities including partnerships, mergers, acquisitions or other transactions.
The company completed the second cohort of its Australian oncology trial and will submit safety data to the independent Data Safety Monitoring Board. No timeline or assurance of a transaction has been established.
Aethlon Medical (Nasdaq: AEMD) will present at the Emerging Growth Conference on February 25, 2026 from 12:30–1:00 PM ET. The live, interactive online presentation features a fireside chat with CEO and CFO Jim Frakes and a real-time Q&A for investors.
Registration is required to attend; an archived webcast will be posted on EmergingGrowth.com and the Emerging Growth YouTube channel after the event.
Aethlon Medical (Nasdaq: AEMD) reported fiscal Q3 results for the period ended December 31, 2025, while advancing clinical and R&D programs. Key facts: cash balance ~$7.0 million, Q3 operating loss of $2.06 million, and nine-month operating expenses down 26.9%. Cohort 2 enrollment in the Australian oncology trial is underway, EV Long COVID preclinical data published on bioRxiv, and an MTA with Stavro is evaluating Hemopurifier compatibility with a simplified blood treatment system.
Aethlon Medical (Nasdaq: AEMD) will release fiscal third quarter results for the period ended December 31, 2025 at 4:15 p.m. ET on February 12, 2026. Management will host a conference call at 4:30 p.m. ET the same day to review results and corporate developments.
Registered participants receive dial-in details; a replay will be available about one hour after the call through March 12, 2026 with conference ID 3024961.
Aethlon Medical (Nasdaq: AEMD) entered a private placement and warrant inducement to raise approximately $3.3 million in gross proceeds, expected to close on or about December 8, 2025. The company agreed to sell 595,897 shares of common stock (or pre-funded warrants) together with warrants to purchase an aggregate 1,042,820 shares at a combined effective offering price of $4.03 per share and accompanying warrant.
The investor agreed to exercise March 2025 warrants for 155,000 shares and September 2025 warrants for 55,555 shares at an amended exercise price of $4.03, and the company will issue 368,471 new unregistered warrants. All warrants will have a $4.03 exercise price and expire 5.5 years after shareholder approval. Maxim Group is sole placement agent.
Aethlon Medical (Nasdaq: AEMD) reported a preclinical ex vivo study (preprint posted 20 Nov 2025) showing the Hemopurifier's GNA affinity resin binds extracellular vesicles (EVs) in Long COVID plasma and decreases seven EV-associated microRNAs linked to inflammatory pathways.
The study found elevated large (100–500 nm) and small (40–200 nm) EVs in Long COVID samples versus recovered controls, increased mannose-positive large EVs, and correlated removal of small EVs by GNA resin. Pathway analysis suggested reduction of inflammatory signaling including JAK-STAT and increased tissue-repair signals. The paper is submitted for peer review.
Aethlon Medical (Nasdaq: AEMD) reported fiscal Q2 results for the period ended September 30, 2025 and provided a corporate update on clinical and research programs.
Key financials include $5.8M cash, a 48% reduction in operating expenses to ~$1.5M for the quarter, and an operating loss of $1.5M vs $2.8M year-ago. Clinical progress includes recruitment of Cohort 2 in the Australian oncology Hemopurifier trial and early biomarker changes observed in 3 initial participants. Collaboration with UCSF on Long COVID EV analysis and an evaluation of Hemopurifier compatibility with a simplified blood treatment system were also announced.
Aethlon Medical (Nasdaq: AEMD) will release fiscal second quarter results for the period ended September 30, 2025 on Wednesday, November 12, 2025 at 4:15 p.m. ET. Management will host a conference call the same day at 4:30 p.m. ET to review results and recent corporate developments, followed by a Q&A.
Registered participants will receive dial-in instructions; toll-free and international dial-in numbers are provided. A replay will be available approximately one hour after the call through December 12, 2025 via the company website or provided dial-in numbers (replay ID 1454680).
The release reiterates that Aethlon is advancing the investigational Hemopurifier, an extracorporeal device targeting enveloped viruses and tumor-derived extracellular vesicles, and notes its U.S. FDA Breakthrough Device Designation for specified oncology and viral indications.